

Singapore-based Genesis MedTech creates new structural heart franchise

07 February 2022 | News

Globally, structural heart disease (SHD) is a major health problem affecting more than 2% of the general population



Singapore-based Genesis MedTech Group has completed the acquisition of JC Medical (JCM), a structural heart company that is primarily engaged in the design and development of transcatheter valve replacement products for the minimally invasive treatment of structural heart diseases.

The acquisition means that Genesis will be able to add J-Valve, a minimally invasive transcatheter aortic valve replacement (TAVR) device for both aortic regurgitation and stenosis patients, to its product portfolio.

This addition will greatly improve Group's ability to better meet the needs of patients, interventional cardiologists, and cardiac surgeons.

J-Valve, developed by JCM, is one of only two companies worldwide, and the first and only in China, to have successfully developed and commercialised a minimally invasive TAVR device approved for both aortic regurgitation and stenosis patients.

Its unique product design minimises stent migration, leading to improved safety and clinical efficacy. On top of this, J-Valve can cater to a wider pool of patients, including patients with low coronary ostium height and small sinuses, as well as those requiring aortic and mitral valve-in-valve procedures.